Stem Cell Dip
Phase 2Biologic
Stem Cell Dip is one of 41 biologic programs targeting Tics. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
108 competitors in Tics
#DrugCompanyPhaseTrials
1Sodium Valproate
AstraZenecaPhase 3
Priftin
SanofiPhase 2
Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Duvyzat
ItalfarmacoPhase 2
Dilaudid
RRhodes Pharmaceuticals, L.P.
Phase 2
Abexinostat
XXynomic Pharmaceuticals, Inc.
Phase 2
Anaprazole
SSihuan Pharmaceutical Holdings Group Ltd.
Phase 3
Dostinex
PfizerPreclinical
HSK39004
Haisco Pharmaceutical Group Co., Ltd.Phase 2
HL-1186
SShanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Stem Cell Dip. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- TTruway Health, Inc.